Drug intelligence / Profile preview

BPR6K471

Development stage: Preclinical
Lead developer: National Health Research Institutes
Modality: Small Molecules
Administration: Intravenous

Overview

BPR6K471 is a pyrimidine-based small molecule inhibitor of Aurora kinases developed by the National Health Research Institutes (NHRI) in Taiwan. It is designed to target both the bulk tumor cells and the cancer stem cell (CSC) subpopulation in small cell lung cancer (SCLC). Preclinical studies have demonstrated that BPR6K471 potently inhibits Aurora kinase activity, leading to reduced expression of stemness markers such as CD133, OCT4, MYC, and Nestin. In vivo, the compound has shown significant tumor growth inhibition in SCLC xenograft models when administered intravenously.

Targets

AURKA (Aurora kinase A)AURKB (Aurora kinase B)AURKC (Aurora kinase C)

Beyond the preview

Go deeper on BPR6K471.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BPR6K471.

Explore the full profile